首页 >> 科研信息 >> 科研论文
Preliminary Clinical Study of Anti-HBV-DC Combine Thymosin-a1 Treating the Inactive HBsAg Carrier
发布时间: 2010-04-02    人气指数:1899

The 20th Conference of the Asian Pacific Association for the Study of the Liver
Poster Presentation(PP231) 

 2010亚肝会海报PP231 

Hepatology International.2010, 4(1):157

 Bang-Fu Wu1,2, Wen-Bao Zhu1, Jiang-Ying Yang2, Fang-Qin Li1, Yun Zhou2, Fu-Xin Lin1, Yan-Ping Fu1, Chun-Qiong Hou1, Hui-Hua Zhou1, Wei Zheng1, Wei Chen1, Jun Yang2, Xue-Song Li1
1Gastroenterology and Hepatology Center, Tongji Medical College Affiliated Dongguan Hospital, Huazhong University of Science and Technology, Liaobu Southwest Road, No. 171-175, Dongguan, China

2 Guangzhou Pubang Biological Immune Technology Research Center, Room 904, D District, Guangzhou International Business Incubator, Guangzhou Science City, Luogang District, Guangzhou, China

        Background:  To observe the treating effects of HBsAg pulsed autologous dendritic cells (anti-HBV-DC) derived from peripheral blood mononuclear cells (PBMC) combine thymosin-a1 for the inactive HBsAg carrier.
        Methods:  Thirteen adult inactive HBsAg carrier included in the study. Taking peripheral venous blood 50 ml, by density gradient centrifugation and adhesion method to obtain PBMC, GM-CSF and IL-4 induced expansion of DC. At the sixth days, a 30 μg HBsAg was give to pulse the DCs. At the seventh days, the anti-HBV-DCs were harvested and were injected into body by subcutaneous and intravenous. Every 2 weeks one time, a total of six times. All patients were injected 1.6 mg thymosin-a1 by subcutaneous, every 1 week 2 times. The HBVM (Time-Resolved Fluorescence Immunoassay, TRFIA), HBV-DNA and liver function were respectively detected at 0, 4, 12 weeks.
        Result:  The total effective rate was 100% (13/13). The serum HBsAg levels were (157.64 ± 221.60) ng/ml, (66.84 ± 86.16) ng/ml (t = 2.20, p = 0.049), and (58.15 ± 88.45) ng/ml (t = 2.29, p = 0.041) at 0, 4, 12 weeks. The serum HBsAg levels were significantly decreased in all patients at 4, 12 weeks. The serum HBsAg negative conversion occurred in 2 patients at 4 weeks, the HBsAg negative conversion rate was 15.39% (2/13). The serum HBsAg negative conversion occurred in other 2 patients at 12 weeks. The total HBsAg negative conversion rate was 30.77% (4/13). The serum HBV-DNA and ALT were normal at 0, 4, 12 weeks.
        Conclusion:  The anti-HBV-DC combine Thymosin-a1 can rapidly decrease and eliminate the blood HBsAg, which were a safe and efficient treatment method for the inactive HBsAg carrier.

  

HBV-DC联合胸腺肽a1治疗非活动性HBsAg携带者的初步临床研究

第20届亚太肝脏研究会年会(北京)

海报展示(PP231) 

Hepatology International.2010, 4(1):157

华中科技大学同济医学院附属东莞医院消化肝病中心  吴邦富 李芳琴 凌佛鑫 朱文宝 付彦平 李雪松 侯春琼 郑硕 陈伟 周慧华

广州普邦生物免疫技术研究院  杨江英 周赟 杨军

    目的 观察HBsAg致敏自体外周血单个核细胞(PBMC)来源的树突状细胞(HBV-DC)联合胸腺肽a1治疗非活动性HBsAg携带者的临床效果。

    方法 非活动性HBsAg携带者13人接受临床研究。男9人,女4人,中位年龄27(18-43)。取肝素抗凝外周静脉血50ml,以密度梯度离心及贴壁法获得PBMCGM-CSFIL-4诱导扩增DC,第6天给予30μgHBsAg致敏DC,第7天收获抗HBV-DC,皮下和静脉各注射1/2。每21次,共6次。皮下注射胸腺肽a1每次1.6mg,每周2次。分别于0412周检测HBVM定量(时间分辨荧光免疫分析技术,TRFIA)HBV-DNA定量及肝功能。

    结果 0412周的HBsAg分别为(157.64±221.60)ng/ml(66.84±86.16)ng/ml(t=2.20P=0.049)(58.15±88.45)ng/ml(t=2.29P=0.041)全部患者治疗后412HBsAg明显下降,其中24周时HBsAg转阴,转阴率15.39(2/13),另212周时HBsAg转阴,总的HBsAg转阴率为30.77(4/13)治疗前后的ALTHBV-DNA定量均正常。有效率100%(13/13)

    结论 HBV-DC联合胸腺肽a1治疗,可快速降低非活动性HBsAg携带者血中HBsAg,部分患者的HBsAg得到清除,是一种安全、有效的治疗非活动性HBsAg携带者的方法。